Monday, 31 August 2026European Markets

METABOLIC EXPLORER Stock Was Up By 11.95% Before The Weekend

Loading stream...

(vianews) - the market ended the session with metabolic explorer (metex.pa) rising 11.95% to €0.41 on friday, following the last session's upward trend. cac 40 jumped 0.7% to €7,966.68, after three consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

metabolic explorer's last close was €0.36, 74.38% below its 52-week high of €1.42.

about metabolic explorer

metabolic explorer s.a., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. the company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and l-valine. its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. the company was incorporated in 1999 and is based in saint-beauzire, france.

earnings per share

as for profitability, metabolic explorer has a trailing twelve months eps of €-0.98.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -42.82%.

moving average

metabolic explorer's worth is higher than its 50-day moving average of €0.39 and way under its 200-day moving average of €0.66.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com